Niemegeers C J, Lenaerts F M, Awouters F, Janssen P A
Arzneimittelforschung. 1975 Oct;25(10):1537-42.
The acute effects of orally administered, high doses of alpha-methyl-4-(2-thienylcarbonyl)benzeneacetic acid (suprofen) were studied in various tests, related to gastrointestinal functions. A decrease of the diarrheal stools in the castor oil test in rats was the first effect noted; the ED50 in this test was 40 mg/kg. This dose is 540 times higher than the ED50 of suprofen in the acetic acid-induced writhing test in rats (ED50 = 0.074 mg/kg). Temporarily decreased food consumption in rats was first noted after administration of 80 mg/kg. This is more than 1000 times the ED50 in the rat anti-writhing test. The appearance of gastrointestinal lesions was also studied in rats and a direct quantitative comparison was made with indometacin, acetyl-salicylic acid and ketoprofen. The dose of suprofen that produced lesions in 50% of the rats was 200 mg/kg, viz. 2700 times the ED50 in the rat anti-writhing test. Similarly obtained safety margins are 9.0 for indometacin, 78 for acetyl-salicylic acid and 102 for ketoprofen. The mortality after a single oral administration of suprofen was studied in mice, rats, guinea-pigs and dogs. LD50-values, based on mortality 7 days after administration, were 590 mg/kg, 353 mg/kg, 280 mg/kg and more than 160 mg/kg, respectively. Comparative LD50's in mice and rats were 14 and 19 mg/kg for indometacin, 280 and 70 mg/kg for ketoprofen. Therefore the safety margin in rats, with respect to the ED50 in the acetic acid-induced writhing test, is 4770 for suprofen, 156 for ketoprofen and 17.3 for indometacin. In guinea-pigs the safety margin of suprofen is 1470 with respect to the ED50 in UV-erythema and in dogs more than 250 with respect to the ED50 in urate-induced arthritis. From these data we may conclude that suprofen is comparatively safer than the reference compounds studied and that its effects on the gastrointestinal tract appear at doses far above those required for effectiveness in tests related to pain, fever and inflammation.
研究了口服高剂量α-甲基-4-(2-噻吩羰基)苯乙酸(舒洛芬)在各种与胃肠功能相关试验中的急性效应。在蓖麻油试验中,大鼠腹泻粪便减少是观察到的首个效应;该试验中的半数有效量(ED50)为40mg/kg。此剂量比舒洛芬在大鼠醋酸诱导扭体试验中的ED50(0.074mg/kg)高540倍。在给予80mg/kg舒洛芬后,首次观察到大鼠的食物摄入量暂时减少。这比大鼠抗扭体试验中的ED50高出1000多倍。还研究了大鼠胃肠道损伤的出现情况,并与吲哚美辛、乙酰水杨酸和酮洛芬进行了直接定量比较。使50%大鼠出现损伤的舒洛芬剂量为200mg/kg,即大鼠抗扭体试验中ED50的2700倍。同样得出的吲哚美辛安全系数为9.0,乙酰水杨酸为78,酮洛芬为102。研究了舒洛芬单次口服给药后在小鼠、大鼠、豚鼠和犬中的死亡率。基于给药7天后的死亡率得出的半数致死量(LD50)值分别为590mg/kg、353mg/kg、280mg/kg和超过160mg/kg。吲哚美辛在小鼠和大鼠中的比较LD50分别为14mg/kg和19mg/kg,酮洛芬分别为280mg/kg和70mg/kg。因此,就醋酸诱导扭体试验中的ED50而言,舒洛芬在大鼠中的安全系数为4770,酮洛芬为156,吲哚美辛为17.3。在豚鼠中,舒洛芬相对于紫外线红斑试验中的ED50的安全系数为1470,在犬中相对于尿酸盐诱导关节炎试验中的ED50的安全系数超过250。从这些数据我们可以得出结论,舒洛芬相对比所研究的参比化合物更安全,并且其对胃肠道的作用出现在远高于与疼痛、发热和炎症相关试验中产生药效所需的剂量。